Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir

Huanhuan Ren; Guiqin Wang; Shuangshuang Wang; Honglin Chen; Zhiwei Chen; Hongxing Hu; Genhong Cheng; Paul Zhou

doi:10.1080/19420862.2016.1183083

journal article May 11, 2016

Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir

Huanhuan Ren Guiqin Wang Shuangshuang Wang

Honglin Chen

Zhiwei Chen

Hongxing Hu Genhong Cheng Paul Zhou

mAbs Vol. 8 No. 6 pp. 1156-1166 · Informa UK Limited

View at Publisher Save 10.1080/19420862.2016.1183083

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

OIE (2016)

[2]

WHO (2016)

[3]

10.3201/eid2105.141927

[4]

10.3201/eid2107.150403

[5]

10.1126/science.aaa6724

[6]

WHO (2016)

[7]

10.1126/science.1135165

[8]

10.1073/pnas.0806901105

[9]

10.1128/jvi.02637-09

[10]

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

Julie E Ledgerwood, Chih-Jen Wei, Zonghui Hu et al.

The Lancet Infectious Diseases 10.1016/s1473-3099(11)70240-7

[11]

10.1073/pnas.1012457108

[12]

10.1128/jvi.06930-11

[13]

10.1093/infdis/jit414

[14]

10.1371/journal.pone.0003942

[15]

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

Jianhua Sui, William C Hwang, Sandra Perez et al.

Nature Structural & Molecular Biology 10.1038/nsmb.1566

[16]

10.1371/journal.pmed.0040178

[17]

10.1371/journal.pone.0005476

[18]

10.1128/jvi.06665-11

[19]

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

Davide Corti, Jarrod Voss, Steven J. Gamblin et al.

Science 10.1126/science.1205669

[20]

Highly Conserved Protective Epitopes on Influenza B Viruses

Cyrille Dreyfus, Nick S. Laursen, Ted Kwaks et al.

Science 10.1126/science.1222908

[21]

10.1128/jvi.01577-13

[22]

10.1128/jvi.02344-12

[23]

10.3201/eid2106.150021

[24]

10.1371/journal.ppat.1000350

[25]

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Xueling Wu, Zhi-Yong Yang, Yuxing Li et al.

Science 10.1126/science.1187659

[26]

10.1128/jvi.01292-12

[27]

10.1038/ncomms9855

[28]

10.1371/journal.pmed.1000049

[29]

Neuraminidase Inhibitors for Influenza

Anne Moscona

New England Journal of Medicine 10.1056/nejmra050740

[30]

10.1128/jvi.00728-15

[31]

10.1146/annurev.med.59.061506.213121

[32]

10.7326/0003-4819-145-8-200610170-00139

[33]

10.1093/infdis/142.6.844

[34]

Sweet C Immunology (1987)

[35]

10.1099/0022-1317-68-10-2681

[36]

10.1056/nejmc070359

[37]

10.1073/pnas.100133697

[38]

10.1371/journal.pone.0016563

[39]

10.1016/j.vaccine.2009.08.056

[40]

Network WGIS (2011)

Metrics

11

Citations

40

References

Details

Published: May 11, 2016
Vol/Issue: 8(6)
Pages: 1156-1166

Authors

State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, China; Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong, China; Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong, China; Department of Microbiology, The University of Hong Kong, Hong Kong, China

Institut Pasteur Shanghai-Chinese Academy of Sciences, Shanghai, China; International Associated Laboratory (LIA VirHost), CNRS, Université Paris-Descartes, and Institut Pasteur Shanghai-Chinese Academy of Sciences, Shanghai, China

Cite This Article

Huanhuan Ren, Guiqin Wang, Shuangshuang Wang, et al. (2016). Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir. mAbs, 8(6), 1156-1166. https://doi.org/10.1080/19420862.2016.1183083

Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir

You May Also Like